(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.8%.
An2 Therapeutics's earnings in 2025 is -$60,697,000.On average, 1 Wall Street analyst forecast ANTX's earnings for 2025 to be -$25,994,634, with the lowest ANTX earnings forecast at -$25,994,634, and the highest ANTX earnings forecast at -$25,994,634. On average, 2 Wall Street analysts forecast ANTX's earnings for 2026 to be -$32,717,385, with the lowest ANTX earnings forecast at -$32,866,779, and the highest ANTX earnings forecast at -$32,567,990.
In 2027, ANTX is forecast to generate -$34,958,301 in earnings, with the lowest earnings forecast at -$34,958,301 and the highest earnings forecast at -$34,958,301.